365 Days of Control: Sequel and Senseonics Redefine Diabetes Care

Diabetes is a lifelong condition affecting millions of people around the world. In type 1 diabetes the body’s immune system attacks the insulin producing beta cells in the pancreas leading to low insulin levels. To manage this condition, continuous monitoring of the glucose is required. Thus, various systems such as continuous glucose monitoring and automated insulin delivery systems are available which help to monitor better glucose levels. However, traditional devices face challenges such as device fatigue, frequent sensor changes, and limited compatibility, thereby hindering the adoption of devices.

On the other hand, various collaborations for developing compatible diabetes care device are growing, leading to major milestone in patient care.

• For instance, Sequel Med Tech, LLC, - involved in developing innovative insulin delivery technologies, and Senseonics Holdings, Inc. - focused on developing implantable continuous glucose monitoring (CGM) systems announced collaboration for development of world’s first 365 days control CGM system (twiist Automated Insulin Delivery (AID) System), offering greater flexibility and personalization.

This collaboration serves common vision: to simplify diabetes management and enhance quality of life of patients suffering from type 1 condition. This system uses innovative technology algorithm based Tidepool Loop, community developed system gaining wide acceptance among users. Further, this twiist Automated Insulin Delivery (AID) System will be commercially available in Q3 2025, following necessary software alignment, regulatory updates and use interface development.

“By combining Eversense’s long duration sensor with ours advanced pump and algorithm, we’re enabling people with diabetes to fully experience the convenience and control of year-long glucose monitoring with an automated system.”- Tim Goodnow, President and CEO of Senseonics

Moreover, this alliance will also focus on patient education, provider training, and awareness campaigns for increasing the adoption of this device and redefining the patient care. This device automatically adjusts basal insulin delivery based on CGM input and predictive glucose modelling, controlling the glucose levels and improving overall diabetes management. This device monitors glucose levels at real-time basis and transmits data every five minutes via mobile app.

“We’re committed to giving people with diabetes more choice in how they, their care. Partnering with Senseonics, a leader in extended wear CGMs, allows us to deliver personalization and flexibility on patient’s terms.” -Alan Lotvin, CEO and Co-Founder of Sequel

Impact on Patients and Providers:

For Patients: The 365-day CGM system offers various benefits to patients, paving the way for personalized, reliable and user-friendly approach for diabetes management.

• Fewer device changes: This device lasts for one year, avoiding the patients to replace the traditional CGMs which need replacing every1-2 weeks.
• Improved treatment adherence: Simplified workflows, fewer system related changes and more consistent glucose data help in adherence to treatment plans.
• Increased confidence in insulin delivery: This device delivers micro-dose along with accurate dosing, thus able to properly manage chronic conditions.

For Providers: This system helps providers for streamlined management and data driven care for chronic conditions such as diabetes.

• Continuous monitoring: Eversense 365 provides continuous monitoring of glucose levels for 365 days, helping the physicians to identify trends, adjust insulin therapy, and make informed decisions based on glycaemic patterns of the patients.
• Fewer appointments: This device requires sensor replacement after one year, reducing the burden on clinicians and focus on impactful aspects of patient care.
• Support for pediatric and adult populations: This device has received FDA clearance, offering flexibility to address each person’s dosing levels.

Thus, twiist Automated Insulin Delivery (AID) System offers greater flexibility, aligning with lifestyle and clinical needs of patients, thereby paving the way for personalize, reliable and more efficient care delivery.